NG101m Adjuvant Therapy in Glioblastoma Patients

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 1, 2027

Primary Completion Date

July 30, 2030

Study Completion Date

December 31, 2030

Conditions
Glioblastoma Multiforme
Interventions
RADIATION

Intensity-modulated radiation therapy

Intensity-modulated radiation therapy (IMRT) in daily fractions of 2.67 Gy given 5 days per week for 3 weeks, for a total of 40.05 Gy.

DRUG

Temozolomide

"Oral temozolomide (75 mg/m2), given 5 days per week, for 3 weeks during radiotherapy.~1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for 12 cycles."

DRUG

NG101m

Oral NG101m capsule continuously twice daily.

Trial Locations (1)

77030

Yvonne Kew MD, PLLC, Houston

Sponsors
All Listed Sponsors
lead

NeuGATE Theranostics

INDUSTRY